AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04907812 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints >50 degree contracture ii. PIP Joints >40 degrees contracture b. >2 fingers involved
Study NCT04907812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints >50 degree contracture ii. PIP Joints >40 degrees contracture b. >2 fingers involved
Study NCT04979962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EW10-EC02 (Endoscopy Support Program)
Description: EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
Study NCT05211245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic ultrasound
Description: Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
Study NCT05211245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultrasound
Description: Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
Study NCT05702372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT05702372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracker made by wheat flour
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT05702372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracker made by rye flour
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT05702372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracker made by sunflower flour
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT04635345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Vibrator - patient-administered.
Description: Patient provided with external vibrator for self-use, as well as vaginal dilators.
Study NCT04635345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
Study NCT04635345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
Study NCT04939532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes.
Study NCT04939532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN)
Description: Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty.
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: CDK4/6 Inhibitor
Study NCT05572541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fonseca questionnaire
Description: Fonseca questionnaire for the evaluation of temporomandibular dysfunction
Study NCT05133206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advice on fasting before the procedure
Description: Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
Study NCT04829461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal
Description: Procedure using a single-use cystoscope for stent removal
Study NCT04829461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care reusable cystoscope used for stent removal
Description: Procedure using a reusable cystoscope for stent removal
Study NCT04679714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (PLAR Implant and Delivery System)
Description: The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
Study NCT04378439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Description: First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention
Study NCT04378439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP.
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 Inhibitor
Study NCT05068388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-Endoxifen
Description: Z-Endoxifen
Study NCT05068388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: CDK4/6 Inhibitor
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK4/6 Inhibitor
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: CDK 4/6 Inhibitor
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4/6 Inhibitor
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Endocrine Therapy
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Endorcine Therapy
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Endocrine Therapy
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Endocrine Therapy
Study NCT06246643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
Study NCT04849416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Administered orally.
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT05564390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive SOC treatment
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04832516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performing following WHO (World Health Organization)
Description: The CLA group will perform exercises following WHO (World Health Organization) prescription
Study NCT04832516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performing on their needs
Description: The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
Study NCT04827810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamitrinib
Description: This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
Study NCT04847141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C19-IG 20%
Description: Anti-COVID-19 Immune Globulin (Human) 20%
Study NCT04847141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium chloride
Description: C19-IG 20% matching placebo
Study NCT04847141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: C19-IG 20% matching placebo
Study NCT04963634 — intervention group
Intervention type: OTHER
Intervention: Biobanking
Description: For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
Study NCT06263790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask
Description: Intubation through a laryngeal mask
Study NCT06263790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Intubation by using a direct laryngoscope
Study NCT05560919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroxycholecalciferols
Description: Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
Study NCT05560919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dimethyl sulfoxide
Description: Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
Study NCT05560919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum
Description: Injection of serum in the periodontal ligament for lower anterior segment teeth.
Study NCT06128070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06128070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography
Description: Undergo chest CT
Study NCT06128070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06128070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT
Study NCT06128070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT06128070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06128070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT06128070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT04359225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D Telemedicine
Description: Telemedicine using 3D broadcast to clinician
Study NCT04359225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2D Telemedicine
Description: Standard care with 2D telemedicine
Study NCT04758975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: VENETOCLAX: Ramp-up than 400 mg QD
Study NCT04758975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
Study NCT04758975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: IBRUTINIB 420 mg QD
Study NCT06049459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Correction
Description: Optical correction (if needed)
Study NCT06049459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Correction
Description: Optical correction (if needed)
Study NCT06049459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Dichoptic Virtual Reality Games
Description: Virtual Reality Game play for amblyopia treatment
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo buccal swab collection
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo buccal swab collection
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT05564390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04631614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm up
Description: Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
Study NCT04631614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm up
Description: Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)